Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2009

View Archived Issues

General Electric claims VMAT2 ligands as imaging agents for the diagnosis of diabetes

Achaogen describes novel aminoglycoside analogues for the treatment of bacterial infections

Rapamycin delays aging in mice

APPRAISE details risk-benefit profile of apixaban in acute coronary syndrome patients

DMCs recommend continuation of PAION's phase IIa and phase Ib studies of CNS-7065

ImmunoVaccine licenses cancer antigens from Immunotope

Capstone completes enrollment in first of two phase II trials of AZX-100 in keloid scarring

FDA issues complete response letter for Watson's NDA for 24-week Trelstar

Array files IND with the FDA to initiate phase I trial of ARRY-162 in cancer

Cornerstone submitted regulatory filing with FDA for antitussive CRTX-067

Cytochroma initiates pharmacokinetic study of CTAP-101 in stage 3 or 4 CKD patients

Merck Serono receives Japanese approval for Gonal-f for ovulation induction in infertile women

Interleukin-7 enhances vaccine-induced antitumor responses in vivo

EnVivo Pharmaceuticals introduces gamma-secretase inhibitors at ICAD

FDA committee reports negative opinion on trabectedin in ovarian cancer

FDA grants second orphan drug designation to Axentis' Fluidosomes in cystic fibrosis

NICE recommends use of Basilea's Toctino for severe chronic hand eczema

FDA committee reports negative opinion on Doxil in breast cancer

Baxter and Halozyme complete enrollment in phase III trial of Gammagard Liquid

Acrux completes phase III trial of testosterone therapy Axiron

Ipsen reports results from phase I and phase IIa clinical studies of BIM23A-760

Actelion reports phase II data for PGI2 receptor agonist in PAH

BSI-201 enters phase III trials for metastatic triple-negative breast cancer

FDA lifts partial clinical hold on Genmab's zalutumumab studies

Cerebrolysin improves clinical outcomes as add-on therapy in mild AD and vascular dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...